Ponatinib: An update on its drug targets, therapeutic potential and safety.

Leukemia is a malignancy of the hematopoietic system, and as its pathogenesis has become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been developed. Ponatinib is the third-generation breakpoint cluster region (BCR) and Abelson (ABL) TKI, which has been influential in the leukemia therapy for a decade. Moreover, ponatinib is a potent multi-target kinase inhibitor that acts on various kinases, such as KIT, RET, and Src, making it a promising treatment option for triple-negative breast cancer (TNBC), lung cancer, myeloproliferative syndrome, and other diseases. The drug's significant cardiovascular toxicity poses a significant challenge to its clinical use, requiring the development of strategies to minimize its toxicity and side effects. In this article, the pharmacokinetics, targets, therapeutic potential, toxicity and production mechanism of ponatinib will be reviewed. Furthermore, we will discuss methods to reduce the drug's toxicity, providing new avenues for research to improve its safety in clinical use. Copyright © 2023. Published by Elsevier B.V.

Citation

Yue Gao, Yue Ding, Xin-Ran Tai, Chen Zhang, Dong Wang. Ponatinib: An update on its drug targets, therapeutic potential and safety. Biochimica et biophysica acta. Reviews on cancer. 2023 Sep;1878(5):188949

Mesh Tags

Substances

PMID: 37399979

search → result